LGND(Ligand Pharmaceuticals Incorporated) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $241.54M | $196.25M | $131.31M | $167.13M | $268.09M |
| 毛利润 | — | — | — | — | — |
| 营业利润 | $103.85M | $3.04M | $11.94M | −$22.61M | $41.00M |
| 净利润 | $57.14M | −$33.36M | $52.15M | −$4.03M | $124.45M |
| 经营现金流 | $78.80M | $137.85M | $49.58M | $97.05M | $49.36M |
| 自由现金流 | $70.04M | $119.93M | $46.06M | $95.23M | $48.91M |
| 摊薄每股收益 | $3.31 | $-1.98 | $2.94 | $-0.22 | $6.13 |